Wilson disease
Rare disease · 2021–2023
7decisions
2medicines
3carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| trientine dihydrochloride Chelation of elevated copper levels in patients with Wilson disease who are intolerant of penicillamine. | Jul 2023 | Recommended | input received |
| trientine dihydrochloride Treatment of Wilson Disease in patients who are intolerant of penicillamine (D-penicillamine). | May 2022 | Deferred | none received |
| trientine tetrahydrochloride Treatment of Wilson's Disease in patients intolerant to D-penicillamine therapy. | May 2022 | Recommended with restriction | none received |
| trientine dihydrochloride Treatment of patients with Wilson Disease who are intolerant of D-penicillamine/penicillamine (DPA). | Mar 2022 | Not recommended | none received |
| trientine tetrahydrochloride Treatment of Wilson Disease in patients intolerant to D-penicillamine therapy, aged 5 years and older. | Mar 2022 | Noted | none received |
| trientine tetrahydrochloride Treatment of patients with Wilson Disease who are intolerant to D-penicillamine/penicillamine, in adults, adolescents and children aged 5 years and older… | Nov 2021 | Not recommended | input received |
| trientine dihydrochloride Treatment of patients with Wilson Disease intolerant to penicillamine/D-penicillamine (DPA) therapy. | Nov 2021 | Not recommended | input received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 7 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.